Lyell Immunopharma is a publicly traded biotechnology enterprise focused on creating novel cell therapies designed to address the underlying causes of treatment failure in cancer care. Founded by prominent life science leaders and researchers, the company applies advanced science in T-cell biology, immunology, and genetic engineering to develop product candidates that prevent T-cell exhaustion. Headquartered in South San Francisco, Lyell operates cutting-edge laboratories and clinical development pipelines aimed at transforming outcomes for patients battling difficult solid tumors and hematological malignancies.